These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26436854)

  • 1. Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis.
    Ramroodi N; Khani M; Ganjali Z; Javan MR; Sanadgol N; Khalseh R; Ravan H; Sanadgol E; Abdollahi M
    Immunol Invest; 2015; 44(7):694-712. PubMed ID: 26436854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS.
    Lee JH; Halperin-Sheinfeld M; Baatar D; Mughal MR; Tae HJ; Kim JW; Carter A; Lustig A; Snir O; Lavie G; Okun E; Mattson MP; Sredni B; Taub DD
    Neuromolecular Med; 2014 Jun; 16(2):292-307. PubMed ID: 24272426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.
    Göbel K; Pankratz S; Schneider-Hohendorf T; Bittner S; Schuhmann MK; Langer HF; Stoll G; Wiendl H; Kleinschnitz C; Meuth SG
    J Autoimmun; 2011 Mar; 36(2):106-14. PubMed ID: 21216565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice.
    Hu X; Qin X
    Int J Mol Med; 2013 May; 31(5):1209-21. PubMed ID: 23525227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE.
    Theien BE; Vanderlugt CL; Nickerson-Nutter C; Cornebise M; Scott DM; Perper SJ; Whalley ET; Miller SD
    Blood; 2003 Dec; 102(13):4464-71. PubMed ID: 12933585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis.
    Matejuk A; Bakke AC; Hopke C; Dwyer J; Vandenbark AA; Offner H
    J Neurosci Res; 2004 Jul; 77(1):119-26. PubMed ID: 15197745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment.
    Castro SB; Junior CO; Alves CC; Dias AT; Alves LL; Mazzoccoli L; Mesquita FP; Figueiredo NS; Juliano MA; Castañon MC; Gameiro J; Almeida MV; Teixeira HC; Ferreira AP
    Int Immunopharmacol; 2012 Feb; 12(2):465-70. PubMed ID: 22245971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis.
    Aminian A; Noorbakhsh F; Ghazi-Khansari M; Kafami L; Javadi S; Hassanzadeh G; Rahimian R; Dehpour AR; Mehr SE
    Neuroscience; 2013 Sep; 248():299-306. PubMed ID: 23774631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis.
    Murphy AC; Lalor SJ; Lynch MA; Mills KH
    Brain Behav Immun; 2010 May; 24(4):641-51. PubMed ID: 20138983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial V-like antigen mediates efficacy of anti-alpha₄ integrin treatment in a mouse model of multiple sclerosis.
    Wright E; Rahgozar K; Hallworth N; Lanker S; Carrithers MD
    PLoS One; 2013; 8(8):e70954. PubMed ID: 23951051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified superantigen rescues Ly6G- CD11b+ blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE.
    Slaney CY; Toker A; Fraser JD; Harper JL; Bäckström BT
    Autoimmunity; 2013 Jun; 46(4):269-78. PubMed ID: 23374140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice.
    Dos Santos AC; Roffê E; Arantes RM; Juliano L; Pesquero JL; Pesquero JB; Bader M; Teixeira MM; Carvalho-Tavares J
    J Neuroinflammation; 2008 Nov; 5():49. PubMed ID: 18986535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone down-regulates spinal cord inflammatory mediators and increases myelination in experimental autoimmune encephalomyelitis.
    Garay LI; González Deniselle MC; Brocca ME; Lima A; Roig P; De Nicola AF
    Neuroscience; 2012 Dec; 226():40-50. PubMed ID: 23000619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation.
    Aarts SABM; Seijkens TTP; Kusters PJH; van der Pol SMA; Zarzycka B; Heijnen PDAM; Beckers L; den Toom M; Gijbels MJJ; Boon L; Weber C; de Vries HE; Nicolaes GAF; Dijkstra CD; Kooij G; Lutgens E
    J Neuroinflammation; 2017 May; 14(1):105. PubMed ID: 28494768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis.
    Bullard DC; Hu X; Schoeb TR; Collins RG; Beaudet AL; Barnum SR
    J Immunol; 2007 Jan; 178(2):851-7. PubMed ID: 17202346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.
    Eltayeb S; Berg AL; Lassmann H; Wallström E; Nilsson M; Olsson T; Ericsson-Dahlstrand A; Sunnemark D
    J Neuroinflammation; 2007 May; 4():14. PubMed ID: 17484785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of neuro inflammation in experimental autoimmune encephalomyelitis by glia maturation factor antibody.
    Zaheer S; Wu Y; Sahu SK; Zaheer A
    Brain Res; 2011 Feb; 1373():230-9. PubMed ID: 21146509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs.
    Thakker P; Marusic S; Stedman NL; Lee KL; McKew JC; Wood A; Goldman SJ; Leach MW; Collins M; Kuchroo VK; Wolf SF; Clark JD; Hassan-Zahraee M
    J Immunol; 2011 Aug; 187(4):1986-97. PubMed ID: 21746963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diminished cytokine and chemokine expression in the central nervous system of GMF-deficient mice with experimental autoimmune encephalomyelitis.
    Zaheer A; Sahu SK; Wu Y; Zaheer A; Haas J; Lee K; Yang B
    Brain Res; 2007 May; 1144():239-47. PubMed ID: 17316572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.
    Li M; Li Y; Liu X; Gao X; Wang Y
    J Neuroimmunol; 2012 Jun; 247(1-2):25-31. PubMed ID: 22516472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.